Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich's Ataxia
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of “Buy” by Brokerages
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Investors Buy Large Volume of Larimar Therapeutics Call Options (NASDAQ:LRMR)
2 Breakout Stocks to Buy Immediately
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
Market Today: Stocks Slide, Oil Majors Rally, Big Deals and FDA Setbacks
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering
Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering
Laminar Therapeutics Stock Is Popping Today: What's Going On?
Larimar Therapeutics (LRMR) Surges On FDA Breakthrough Therapy Designation
Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026
Head-To-Head Survey: Oncology Pharma (OTCMKTS:ONPH) vs. Larimar Therapeutics (NASDAQ:LRMR)
Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care
Larimar Therapeutics, Inc. (LRMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Rating of “Moderate Buy” by Analysts
Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Larimar Therapeutics Reports Third Quarter 2025 Financial Results
Ethic Inc. Invests $187,000 in Larimar Therapeutics, Inc. $LRMR
Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LRMR
LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – LRMR
LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
Larimar Therapeutics, Inc. - Special Call
Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal Study
Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich's Ataxia
Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia
Larimar Therapeutics Reports Second Quarter 2025 Financial Results
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
Larimar Therapeutics Announces Pricing of Underwritten Public Offering
Larimar Therapeutics Announces Proposed Underwritten Public Offering
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia
Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program
Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia
Larimar Therapeutics Reports First Quarter 2025 Financial Results
Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia